Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year of life, deprescribing antithrombotic therapy at the end of life is rare in practice. It is often continued until death, possibly resulting in excess bleeding, an increased disease burden and higher healthcare costs.

Source: Thrombosis Research - May 12, 2023 Category: Hematology Authors: J. Goedegebuur, D. Abbel, S. Accassat, W.P. Achterberg, A. Akbari, E. Baddeley, J.J. Bax, D. Becker, B. Bergmeijer, L. Bertoletti, J.W. Blom, A. Calvetti, S.C. Cannegieter, L. Castro, N.H. Chavannes, N. Coma-Auli, C. Couffignal, A. Edwards, M. Edwards, H. Tags: Full Length Article Source Type: research